Moderna-Merck cancer vaccine success marks breakthrough for personalised mRNA treatment
A PERSONALISED mRNA-based cancer vaccine developed by Moderna and Merck & Co. has delivered a landmark result in a late-stage melanoma trial, strengthening hopes that technology originally propelled into the mainstream by Covid-19 vaccines could even...
Moderna and Merck & Co. have achieved a significant breakthrough with a personalized mRNA-based cancer vaccine, displaying success in a large-scale melanoma trial. This marks the first time an mRNA-based cancer vaccine has demonstrated efficacy in such a study, instilling optimism in the potential of mRNA technology to combat cancer.
The vaccine, designed to treat existing cancer patients, works by reducing recurrence rates after surgery by training the immune system to target tumour-specific mutations, known as neoantigens. This personalised approach, which tailors the vaccine to each patient's tumour, differs from traditional cancer treatments like chemotherapy and immunotherapy.
Initial results have sparked investor optimism, with Moderna shares surging 177% following the announcement. While the full results are pending, researchers are hopeful that the vaccine could extend patient survival and provide more effective treatment options. The trial continues to gather long-term data, and similar mRNA cancer vaccines are being developed by other companies like BioNTech and Roche.
Despite the significant findings, the technology is not yet a cure for cancer, but the results offer strong clinical evidence that personalized mRNA vaccines can train the immune system to recognize and attack individual tumours.
Written by urgent.news from The Vibes's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
